Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis
Authors:
- Vera M. R. HeydendaelVHVera M. R. Heydendael
- Corianne A. J. M. de BorgieCBCorianne A. J. M. de Borgie
- Phyllis I. SpulsPSPhyllis I. Spuls
- Patrick M. M. BossuytPBPatrick M. M. Bossuyt
- Jan D. BosJBJan D. Bos
- Menno A. de RieMRMenno A. de Rie
Open Access
- 1 June 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 140 (6) , 685-690
Abstract
PSORIASIS IS a chronic disease for which only remissive, as opposed to curative, treatments are currently available. Methotrexate and cyclosporine are now the predominant systemic treatment modalities for patients with moderate to severe psoriasis. They have been used as such for the past 40 and 20 years, respectively. Therapy with methotrexate has been evaluated in noncomparative trials, reporting effective induction and maintenance of remission in patients with severe psoriasis.1 In addition, there is strong evidence supporting the use of cyclosporine, and optimal dosage and treatment schemes for cyclosporine have been systematically assessed.2Keywords
This publication has 10 references indexed in Scilit:
- Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque PsoriasisNew England Journal of Medicine, 2003
- Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexateJournal of the American Academy of Dermatology, 2002
- Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled studyArthritis & Rheumatism, 2001
- Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implicationsBritish Journal of Dermatology, 2001
- Pharmacoeconomic Evaluation of Calcipotriol (Daivonex®/Dovonex®) and UVB Phototherapy in the Treatment of Psoriasis: A Markov Model for The NetherlandsDermatology, 2001
- Patient Compliance and Disease Management in the Treatment of Psoriasis in the NetherlandsDermatology, 2000
- A systematic review of treatments for severe psoriasis.Health Technology Assessment, 2000
- Labor and Health Status in Economic Evaluation of Health Care: The Health and Labor QuestionnaireInternational Journal of Technology Assessment in Health Care, 1996
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978